Bank of New York Mellon Corp Decreases Stock Holdings in Balchem Corporation (NASDAQ:BCPC)

Bank of New York Mellon Corp lessened its holdings in shares of Balchem Corporation (NASDAQ:BCPC - Free Report) by 2.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 237,106 shares of the basic materials company's stock after selling 6,521 shares during the quarter. Bank of New York Mellon Corp owned about 0.73% of Balchem worth $39,360,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Covestor Ltd raised its holdings in shares of Balchem by 93.8% during the 4th quarter. Covestor Ltd now owns 157 shares of the basic materials company's stock worth $26,000 after acquiring an additional 76 shares in the last quarter. Federated Hermes Inc. bought a new position in shares of Balchem during the 4th quarter valued at approximately $33,000. Versant Capital Management Inc increased its position in shares of Balchem by 534.2% during the 1st quarter. Versant Capital Management Inc now owns 241 shares of the basic materials company's stock valued at $40,000 after purchasing an additional 203 shares during the last quarter. Huntington National Bank increased its position in shares of Balchem by 30.9% during the 4th quarter. Huntington National Bank now owns 661 shares of the basic materials company's stock valued at $108,000 after purchasing an additional 156 shares during the last quarter. Finally, Quadrant Capital Group LLC increased its position in shares of Balchem by 8.2% during the 4th quarter. Quadrant Capital Group LLC now owns 989 shares of the basic materials company's stock valued at $161,000 after purchasing an additional 75 shares during the last quarter. Institutional investors own 87.91% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on BCPC. Wall Street Zen downgraded Balchem from a "buy" rating to a "hold" rating in a research report on Wednesday, May 21st. HC Wainwright set a $180.00 target price on Balchem and gave the company a "buy" rating in a research report on Monday, April 28th.

Balchem Trading Down 3.5%

Balchem stock traded down $5.49 during mid-day trading on Friday, hitting $152.88. The company's stock had a trading volume of 81,292 shares, compared to its average volume of 143,026. The company has a 50 day moving average of $163.37 and a 200-day moving average of $162.72. The stock has a market cap of $4.99 billion, a PE ratio of 36.63, a P/E/G ratio of 3.41 and a beta of 0.89. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.40 and a current ratio of 2.44. Balchem Corporation has a one year low of $145.70 and a one year high of $186.03.

Balchem (NASDAQ:BCPC - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The basic materials company reported $1.22 EPS for the quarter, missing the consensus estimate of $1.25 by ($0.03). The business had revenue of $250.52 million during the quarter, compared to the consensus estimate of $245.70 million. Balchem had a net margin of 14.16% and a return on equity of 12.01%. The business's revenue was up 4.5% compared to the same quarter last year. During the same period last year, the company earned $1.03 EPS. On average, research analysts anticipate that Balchem Corporation will post 4.64 EPS for the current year.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.